Nkarta (NKTX) Expected to Announce Earnings on Thursday

Nkarta (NASDAQ:NKTX) will likely be releasing its earnings data before the market opens on Thursday, March 20th. Analysts expect Nkarta to post earnings of ($0.39) per share for the quarter.

Nkarta Stock Down 5.6 %

Shares of NASDAQ:NKTX opened at $1.53 on Wednesday. Nkarta has a 52-week low of $1.51 and a 52-week high of $13.90. The stock has a market cap of $107.97 million, a price-to-earnings ratio of -0.81 and a beta of 0.90. The business has a 50-day moving average price of $2.11 and a 200-day moving average price of $3.04.

Wall Street Analyst Weigh In

Separately, Mizuho reduced their price objective on Nkarta from $20.00 to $16.00 and set an “outperform” rating for the company in a research note on Thursday, November 21st. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $15.00.

Insider Buying and Selling

In related news, CEO Paul J. Hastings sold 17,378 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total transaction of $38,231.60. Following the sale, the chief executive officer now directly owns 319,859 shares of the company’s stock, valued at $703,689.80. This trade represents a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 8.70% of the stock is owned by corporate insiders.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.